Top

Published in:

01-07-2015 | Original Article

Galanin receptor 2-neuropeptide Y Y1 receptor interactions in the amygdala lead to increased anxiolytic actions

Authors: Manuel Narváez, Carmelo Millón, Dasiel Borroto-Escuela, Antonio Flores-Burgess, Luis Santín, Concepción Parrado, Belén Gago, Araceli Puigcerver, Kjell Fuxe, José Angel Narváez, Zaida Díaz-Cabiale

Published in: Brain Structure and Function | Issue 4/2015

Abstract

Galanin (GAL) and neuropeptide Y (NPY) are neuropeptides involved in behaviors associated with anxiety. Both neuropeptides interact in several central functions. However, the potential behavioral and cellular interactions between them in anxiety are unknown. GAL was found to act through GAL receptor 2 (GALR2) to enhance NPYY1 receptor (NPYY1R)-mediated anxiolytic behaviors in rats. Using receptor autoradiography, c-Fos expression and in situ proximity ligation assay, the medial paracapsular intercalated nuclei of the amygdala were determined to be a key area in the interaction probably involving the formation of GALR2/NPYY1R heteroreceptor complexes. In cell cultures costimulation of GALR2 and NPYY1R induced changes in the functions of these receptors. The changes involved a potentiation of the decrease in the phosphorylation of CREB induced by NPYY1R and a delay in the internalization of NPYY1R. These results indicate that GALR2/NPYY1R interactions can provide a novel integrative amygdaloid mechanism in anxiety.

Available only for authorised users

AbdAlla S, Abdel-Baset A, Lother H, el Massiery A, Quitterer U (2005) Mesangial AT1/B2 receptor heterodimers contribute to angiotensin II hyperresponsiveness in experimental hypertension. J Mol Neurosci 26(2–3):185–192. doi:10.1385/JMN:26:2-3:185 PubMedCrossRef

Bailey KR, Pavlova MN, Rohde AD, Hohmann JG, Crawley JN (2007) Galanin receptor subtype 2 (GalR2) null mutant mice display an anxiogenic-like phenotype specific to the elevated plus-maze. Pharmacol Biochem Behav 86(1):8–20. doi:10.1016/j.pbb.2006.11.024 PubMedCentralPubMedCrossRef

Barrera G, Echevarria DJ, Poulin JF, Laforest S, Drolet G, Morilak DA (2005) One for all or one for one: does co-transmission unify the concept of a brain galanin “system” or clarify any consistent role in anxiety? Neuropeptides 39(3):289–292. doi:10.1016/j.npep.2004.12.008 PubMedCrossRef

Bing O, Moller C, Engel JA, Soderpalm B, Heilig M (1993) Anxiolytic-like action of centrally administered galanin. Neurosci Lett 164(1–2):17–20 0304-3940(93)90846-DPubMedCrossRef

Blackshear A, Yamamoto M, Anderson BJ, Holmes PV, Lundstrom L, Langel U, Robinson JK (2007) Intracerebroventricular administration of galanin or galanin receptor subtype 1 agonist M617 induces c-Fos activation in central amygdala and dorsomedial hypothalamus. Peptides 28(5):1120–1124. doi:10.1016/j.peptides.2007.01.015 PubMedCrossRef

Borroto-Escuela DO, Narvaez M, Marcellino D, Parrado C, Narvaez JA, Tarakanov AO, Agnati LF, Diaz-Cabiale Z, Fuxe K (2010) Galanin receptor-1 modulates 5-hydroxtryptamine-1A signaling via heterodimerization. Biochem Biophys Res Commun 393(4):767–772. doi:10.1016/j.bbrc.2010.02.078 PubMedCrossRef

Borroto-Escuela DO, Romero-Fernandez W, Mudo G, Perez-Alea M, Ciruela F, Tarakanov AO, Narvaez M, Di Liberto V, Agnati LF, Belluardo N, Fuxe K (2012) Fibroblast growth factor receptor 1–5-hydroxytryptamine 1A heteroreceptor complexes and their enhancement of hippocampal plasticity. Biol Psychiatry 71(1):84–91. doi:10.1016/j.biopsych.2011.09.012 PubMedCrossRef

Broqua P, Wettstein JG, Rocher MN, Gauthier-Martin B, Junien JL (1995) Behavioral effects of neuropeptide Y receptor agonists in the elevated plus-maze and fear-potentiated startle procedures. Behav Pharmacol 6(3):215–222PubMedCrossRef

Diaz-Cabiale Z, Parrado C, Rivera A, de la Calle A, Agnati L, Fuxe K, Narvaez JA (2006) Galanin-neuropeptide Y (NPY) interactions in central cardiovascular control: involvement of the NPY Y receptor subtype. Eur J Neurosci 24(2):499–508. doi:10.1111/j.1460-9568.2006.04937.x PubMedCrossRef

Diaz-Cabiale Z, Parrado C, Narvaez M, Puigcerver A, Millon C, Santin L, Fuxe K, Narvaez JA (2011) Galanin receptor/neuropeptide Y receptor interactions in the dorsal raphe nucleus of the rat. Neuropharmacology 61(1–2):80–86. doi:10.1016/j.neuropharm.2011.03.002 PubMedCrossRef

Dumont Y, Fournier A, St-Pierre S, Quirion R (1996) Autoradiographic distribution of [¹²⁵I]Leu31, Pro34 PYY and [¹²⁵I]PYY3-36 binding sites in the rat brain evaluated with two newly developed Y1 and Y2 receptor radioligands. Synapse 22(2):139–158PubMedCrossRef

Fuxe K, Borroto-Escuela DO, Romero-Fernandez W, Tarakanov AO, Calvo F, Garriga P, Tena M, Narvaez M, Millon C, Parrado C, Ciruela F, Agnati LF, Narvaez JA, Diaz-Cabiale Z (2012) On the existence and function of galanin receptor heteromers in the central nervous system. Front Endocrinol (Lausanne) 3:127. doi:10.3389/fendo.2012.00127

Gehlert DR, Schober DA, Morin M, Berglund MM (2007) Co-expression of neuropeptide Y Y1 and Y5 receptors results in heterodimerization and altered functional properties. Biochem Pharmacol 74(11):1652–1664. doi:10.1016/j.bcp.2007.08.017 PubMedCrossRef

Heilig M (1995) Antisense inhibition of neuropeptide Y (NPY)-Y1 receptor expression blocks the anxiolytic-like action of NPY in amygdala and paradoxically increases feeding. Regul Pept 59(2):201–205 016701159500103IPubMedCrossRef

Heilig M, McLeod S, Brot M, Heinrichs SC, Menzaghi F, Koob GF, Britton KT (1993) Anxiolytic-like action of neuropeptide Y: mediation by Y1 receptors in amygdala, and dissociation from food intake effects. Neuropsychopharmacology 8(4):357–363. doi:10.1038/npp.1993.35 PubMedCrossRef

Holmes A, Picciotto MR (2006) Galanin: a novel therapeutic target for depression, anxiety disorders and drug addiction? CNS Neurol Disord Drug Targets 5(2):225–232PubMedCrossRef

Holmes A, Kinney JW, Wrenn CC, Li Q, Yang RJ, Ma L, Vishwanath J, Saavedra MC, Innerfield CE, Jacoby AS, Shine J, Iismaa TP, Crawley JN (2003) Galanin GAL-R1 receptor null mutant mice display increased anxiety-like behavior specific to the elevated plus-maze. Neuropsychopharmacology 28(6):1031–1044. doi:10.1038/sj.npp.1300164 PubMed

Jacobowitz DM, Kresse A, Skofitsch G (2004) Galanin in the brain: chemoarchitectonics and brain cartography––a historical review. Peptides 25(3):433–464. doi:10.1016/j.peptides.2004.02.015 PubMedCrossRef

Karlsson RM, Holmes A, Heilig M, Crawley JN (2005) Anxiolytic-like actions of centrally-administered neuropeptide Y, but not galanin, in C57BL/6 J mice. Pharmacol Biochem Behav 80(3):427–436. doi:10.1016/j.pbb.2004.12.009 PubMedCrossRef

Karlsson RM, Choe JS, Cameron HA, Thorsell A, Crawley JN, Holmes A, Heilig M (2008) The neuropeptide Y Y1 receptor subtype is necessary for the anxiolytic-like effects of neuropeptide Y, but not the antidepressant-like effects of fluoxetine, in mice. Psychopharmacology 195(4):547–557. doi:10.1007/s00213-007-0945-2 PubMedCrossRef

Kask A, Harro J, von Horsten S, Redrobe JP, Dumont Y, Quirion R (2002) The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y. Neurosci Biobehav Rev 26(3):259–283 S0149763401000665PubMedCrossRef

Khoshbouei H, Cecchi M, Morilak DA (2002) Modulatory effects of galanin in the lateral bed nucleus of the stria terminalis on behavioral and neuroendocrine responses to acute stress. Neuropsychopharmacology 27(1):25–34. doi:10.1016/S0893-133X(01)00424-9 PubMedCrossRef

Kuteeva E, Wardi T, Lundstrom L, Sollenberg U, Langel U, Hokfelt T, Ogren SO (2008) Differential role of galanin receptors in the regulation of depression-like behavior and monoamine/stress-related genes at the cell body level. Neuropsychopharmacology 33(11):2573–2585. doi:10.1038/sj.npp.1301660 PubMedCrossRef

Leibowitz SF (2005) Regulation and effects of hypothalamic galanin: relation to dietary fat, alcohol ingestion, circulating lipids and energy homeostasis. Neuropeptides 39(3):327–332. doi:10.1016/j.npep.2004.12.022 PubMedCrossRef

Lu X, Ross B, Sanchez-Alavez M, Zorrilla EP, Bartfai T (2008) Phenotypic analysis of GalR2 knockout mice in anxiety- and depression-related behavioral tests. Neuropeptides 42(4):387–397. doi:10.1016/j.npep.2008.04.009 PubMedCentralPubMedCrossRef

Madaan V, Wilson DR (2009) Neuropeptides: relevance in treatment of depression and anxiety disorders. Drug News Perspect 22(6):319–324. doi:10.1358/dnp.2009.22.6.1395255 PubMedCrossRef

Mathew SJ, Price RB, Charney DS (2008) Recent advances in the neurobiology of anxiety disorders: implications for novel therapeutics. Am J Med Genet C Semin Med Genet 148C(2):89–98. doi:10.1002/ajmg.c.30172 PubMedCrossRef

Moller C, Sommer W, Thorsell A, Heilig M (1999) Anxiogenic-like action of galanin after intra-amygdala administration in the rat. Neuropsychopharmacology 21(4):507–512. doi:10.1016/S0893-133X(98)00102-X PubMedCrossRef

Morilak DA, Cecchi M, Khoshbouei H (2003) Interactions of norepinephrine and galanin in the central amygdala and lateral bed nucleus of the stria terminalis modulate the behavioral response to acute stress. Life Sci 73(6):715–726 S0024320503003928PubMedCrossRef

O’Donnell D, Ahmad S, Wahlestedt C, Walker P (1999) Expression of the novel galanin receptor subtype GALR2 in the adult rat CNS: distinct distribution from GALR1. J Comp Neurol 409(3):469–481. doi:10.1002/(SICI)1096-9861(19990705)409:3<469:AID-CNE10>3.0.CO;2-Q PubMedCrossRef

Palomares-Castillo E, Hernandez-Perez OR, Perez-Carrera D, Crespo-Ramirez M, Fuxe K, Perez de la Mora M (2012) The intercalated paracapsular islands as a module for integration of signals regulating anxiety in the amygdala. Brain Res 1476:211–234. doi:10.1016/j.brainres.2012.03.047 PubMedCrossRef

Parker SL, Parker MS, Sah R, Balasubramaniam A, Sallee FR (2008) Pertussis toxin induces parallel loss of neuropeptide Y Y1 receptor dimers and Gi alpha subunit function in CHO cells. Eur J Pharmacol 579(1–3):13–25. doi:10.1016/j.ejphar.2007.10.002 PubMedCrossRef

Parrado C, Diaz-Cabiale Z, Garcia-Coronel M, Agnati LF, Covenas R, Fuxe K, Narvaez JA (2007) Region specific galanin receptor/neuropeptide Y Y1 receptor interactions in the tel- and diencephalon of the rat. Relevance for food consumption. Neuropharmacology 52(2):684–692. doi:10.1016/j.neuropharm.2006.09.010 PubMedCrossRef

Paxinos GWC (1986) The rat brain in stereotaxic coordinates. Academic, New York

Rotzinger S, Lovejoy DA, Tan LA (2010) Behavioral effects of neuropeptides in rodent models of depression and anxiety. Peptides 31(4):736–756. doi:10.1016/j.peptides.2009.12.015 PubMedCrossRef

Sajdyk TJ, Vandergriff MG, Gehlert DR (1999) Amygdalar neuropeptide Y Y1 receptors mediate the anxiolytic-like actions of neuropeptide Y in the social interaction test. Eur J Pharmacol 368(2–3):143–147PubMedCrossRef

Swanson LW (1992) Brain maps: structure of the rat brain. Elsevier, Amsterdam

Swanson CJ, Blackburn TP, Zhang X, Zheng K, Xu ZQ, Hokfelt T, Wolinsky TD, Konkel MJ, Chen H, Zhong H, Walker MW, Craig DA, Gerald CP, Branchek TA (2005) Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299. Proc Natl Acad Sci USA 102(48):17489–17494. doi:10.1073/pnas.0508970102 PubMedCentralPubMedCrossRef

Thorsell A, Heilig M (2002) Diverse functions of neuropeptide Y revealed using genetically modified animals. Neuropeptides 36(2–3):182–193 (S0143417902908978)PubMedCrossRef

Wirz SA, Davis CN, Lu X, Zal T, Bartfai T (2005) Homodimerization and internalization of galanin type 1 receptor in living CHO cells. Neuropeptides 39(6):535–546. doi:10.1016/j.npep.2005.09.001 PubMedCrossRef

Wrenn CC, Holmes A (2006) The role of galanin in modulating stress-related neural pathways. Drug News Perspect 19(8):461–467. doi:10.1358/dnp.2006.19.8.1043963 PubMedCrossRef

Title: Galanin receptor 2-neuropeptide Y Y1 receptor interactions in the amygdala lead to increased anxiolytic actions
Authors: Manuel Narváez
Carmelo Millón
Dasiel Borroto-Escuela
Antonio Flores-Burgess
Luis Santín
Concepción Parrado
Belén Gago
Araceli Puigcerver
Kjell Fuxe
José Angel Narváez
Zaida Díaz-Cabiale
Publication date: 01-07-2015
Publisher: Springer Berlin Heidelberg
Published in: Brain Structure and Function / Issue 4/2015
Print ISSN: 1863-2653
Electronic ISSN: 1863-2661
DOI: https://doi.org/10.1007/s00429-014-0788-7

At a glance: The STEP trials

Springer Medicine

Galanin receptor 2-neuropeptide Y Y1 receptor interactions in the amygdala lead to increased anxiolytic actions

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2015

Combinatorial analysis of calcium-binding proteins in larval and adult zebrafish primary olfactory system identifies differential olfactory bulb glomerular projection fields

Reorganization of supramammillary–hippocampal pathways in the rat pilocarpine model of temporal lobe epilepsy: evidence for axon terminal sprouting

Multimodal neuroimaging in humans at 9.4 T: a technological breakthrough towards an advanced metabolic imaging scanner

Activity-dependent and graded BACE1 expression in the olfactory epithelium is mediated by the retinoic acid metabolizing enzyme CYP26B1

Virtual Electrode Recording Tool for EXtracellular potentials (VERTEX): comparing multi-electrode recordings from simulated and biological mammalian cortical tissue

Abnormalities in structural covariance of cortical gyrification in schizophrenia